drugset
drugset / Trial / NCT06314906

Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

NCT06314906 ↗

Phase 3 Recruiting 370 enrolled Feixue Song
RandomizedParallel-groupTriple-blindTreatment

Summary

This study explores the effectiveness of combining electroacupuncture with olanzapine-containing four-drug antiemetic therapy to mitigate chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The research aims to assess the adjunctive benefits of electroacupuncture in enhancing the antiemetic effects of conventional medication, particularly in the context of highly emetogenic chemotherapy regimens. By investigating the synergistic potential of these modalities, the study seeks to provide insights into optimizing supportive care strategies for patients with breast cancer undergoing intensive chemotherapy treatment.

Timeline

Start
2024-03-07
Primary completion
2027-01-31
Completion
2027-03-31

Drugs

EvaluationDrugModalityDoseRoute
Background Dexamethasone Small molecule 8 mg Intravenous
Background Olanzapine Small molecule 5 mg Oral

Indications

No indication recorded.